Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Ligand Pharmaceuticals Inc.    LGND

Delayed Quote. Delayed  - 09/30 10:00:00 pm
102.06 USD   +0.05%
09/25 LIGAND PHARMACE : Blue Clay Capital Management Lowers stake in Ligan..
09/23 LIGAND PHARMACE : Pharma (LGND) Enters Licensing Agreements with See..
09/22 LIGAND PHARMACE : Licenses Four Programs to Seelos Therapeutics
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Ligand Pharmaceuticals Inc. : SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Breaches of Fiduciary Duty by the Board of Directors of Ligand Pharmaceuticals Incorporated

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/17/2013 | 06:55pm CEST

NEW YORK, May 17, 2013 /PRNewswire/ -- Levi & Korsinsky, LLP is investigating Ligand Pharmaceuticals Incorporated (NasdaqGM: LGND), and its Board of Directors, in connection with possible claims of breaches of fiduciary duty.

(Logo: http://photos.prnewswire.com/prnh/20120409/MM84375LOGO)

To get more information, click here: http://zlk.9nl.com/ligand-pharmaceuticals-lgnd/. There is no cost or obligation to you.

If you own common stock in Ligand Pharmaceuticals Incorporated and wish to obtain additional information, please contact Eduard Korsinsky, Esq. either via email at ek@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/ligand-pharmaceuticals-lgnd/.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, and Washington D.C. The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. The attorneys at Levi & Korsinsky have been appointed by numerous courts throughout the country to serve as lead counsel on behalf of shareholders in major securities lawsuits and have successfully recovered multimillion-dollar damages awards on behalf of investors. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Eduard Korsinsky, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE Levi & Korsinsky, LLP

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on LIGAND PHARMACEUTICALS INC
09/25 LIGAND PHARMACEUTICALS : Blue Clay Capital Management Lowers stake in Ligand Pha..
09/23 LIGAND PHARMACEUTICALS : Pharma (LGND) Enters Licensing Agreements with Seelos T..
09/22 LIGAND PHARMACEUTICALS INC : Change in Directors or Principal Officers (form 8-K..
09/22 LIGAND PHARMACEUTICALS INC : Other Events (form 8-K)
09/22 LIGAND PHARMACEUTICALS : Licenses Four Programs to Seelos Therapeutics
09/16 LIGAND PHARMACEUTICALS : Enters OmniAb® License Agreement with TeneoBio, Inc.
09/13 LIGAND PHARMACEUTICALS : Initiates Phase 2 Trial with LGD-6972 in Type 2 Diabete..
09/07 LIGAND PHARMACEUTICALS : Partner Retrophin Announces Positive Top-Line Results f..
09/02 LIGAND PHARMACEUTICALS : to Participate in Two Upcoming Investor Conferences
08/26 LIGAND PHARMACEUTICALS INC : Changes in Registrant's Certifying Accountant, Fina..
More news
Sector news : Biotechnology & Medical Research - NEC
09/29DJARROWHEAD PHARMACEUTICALS : Amgen, Arrowhead Pharma Agree to Cardiovascular Coll..
09/27DJAMGEN : Myeloma Treatment Study Fails to Meet Primary Endpoint
09/26DJSANOFI : FDA Accepts Sanofi's, Regeneron's Dermatitis Treatment for Priority Rev..
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
09/28 BIOTECH FORUM DAILY DIGEST : Notable Trial Failures; NASH Continues To Be Tough ..
09/27 Midday Gainers / Losers
09/27 Ligand Pharma down 9% on failure of Amgen's Phase 3 Kyprolis study
09/27 HEALTHCARE - TOP GAINERS / LOSERS AS : 00 am
09/22 BEST NEAR-TERM PRICE GAINS AHEAD FOR : Biotech Stocks